BioPorto A/S (THOXF)

Revenue by Product

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 1997	Dec 31, 1996	Dec 31, 1995
Neutrophil Gelatinase-associated Lipocalin Tests	23.05M
Neutrophil Gelatinase-associated Lipocalin Tests Growth	24.23%
Antibodies	10.78M
Antibodies Growth	0.95%
Enzyme-linked Immunosorbent Assay Kits	2.27M
Enzyme-linked Immunosorbent Assay Kits Growth	35.54%
Royalty and Other	137.00K
Royalty and Other Growth	204.44%

Revenue by Geography

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 1997	Dec 31, 1996	Dec 31, 1995
United States	20.50M
United States Growth	18.50%
Europe	10.24M
Europe Growth	5.48%
Asia	5.37M
Asia Growth	42.34%
North America	134.00K
North America Growth	-25.14%